The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Objective: To evaluate the value of positron emission tomography/computed tomography (PET/CT) in predicting no residual disease (NRD) after secondary cytoreductive surgery (SCS) compared with MSK criteria, the iMODEL, and the AGO score.
Methods: We analyzed 112 patients with platinum-sensitive ovarian carcinoma who underwent SCS. We excluded patients for whom PET/CT was not performed, those without sufficient data, and who received chemotherapy before SCS. Ultimately, 69 patients were included.
Results: Variables that correlated with NRD were peritoneal carcinomatosis index (odds ratio [OR]=0.91; 95% confidence interval [CI]=0.83–0.99; p=0.044), European Cooperative Oncology Group Performance Status (ECOG) 0 (OR=8.0; 95% CI=1.34–47.5; p=0.022), and ≤2 lesions by PET/CT (OR=4.36; 95% CI=1.07–17.7; p=0.039). Of the patients with ≤2 lesions by PET/CT, 48 (92.3%) underwent complete SCS. The sensitivity, positive predictive value, negative predictive value, and accuracy of PET/CT for NRD were 85.7%, 92.3%, 33.3%, and 81.2%, respectively. NRD was achieved after fulfilling the MSK criteria, iMODEL and AGO Score in 89.1%, 88.1% and 85.9%, respectively. The accuracy of the MSK criteria, iMODEL, and AGO score in predicting NRD was 87%, 83.3%, and 77.3%, respectively. The PET/CT findings agreed well with the AGO score and iMODEL. The addition of PET/CT to these models increased the NRD rates (92.2%, 91.8%, and 89.4% for MSK+PET/CT, iMODEL+PET/CT, and AGO+PET/CT, respectively), but lowered their accuracy.
Conclusion: We observed NRD in 92.3% of patients with ≤2 lesions by PET/CT, with an accuracy of 81.2%. PET/CT did not increase the accuracy of the MSK criteria, iMODEL, or AGO score models.

번역하기

참고문헌 (Reference)

1 Cho SM, "Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer" 179 : 391-395, 2002

2 Simcock B, "The impact of PET/CT in the management of recurrent ovarian cancer" 103 : 271-276, 2006

3 Fulham MJ, "The impact of PET-CT in suspected recurrent ovarian cancer : a prospective multi-centre study as part of the Australian PET Data Collection Project" 112 : 462-468, 2009

4 Harter P, "Surgery in recurrent ovarian cancer : the Arbeitsgemeinschaft Gynaekologische Onkologie(AGO)DESKTOP OVAR trial" 13 : 1702-1710, 2006

5 Coleman RL, "Secondary surgical cytoreduction for recurrent ovarian cancer" 381 : 1929-1939, 2019

6 Baek MH, "Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer : a meta-analysis" 40 : 1659-1670, 2022

7 Shi T, "Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer(SOC-1) : a multicentre, openlabel, randomised, phase 3 trial" 22 : 439-449, 2021

8 Son H, "Role of FDG PET/CT in staging of recurrent ovarian cancer" 31 : 569-583, 2011

9 Fagotti A, "Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer(SCORPIONNCT01461850)" 30 : 1657-1664, 2020

10 Harter P, "Randomized trial of cytoreductive surgery for relapsed ovarian cancer" 385 : 2123-2131, 2021